Medicine sales topped $1 billion for the first time at Neurocrine
Neurocrine reported Q3 2026 revenue of $1.123B, up 41% YoY, driven by INGREZZA ($801M) and CRENESSITY ($211M) sales. GAAP net income was $207M, down from $210M YoY. Non-GAAP EPS rose to $3.29. The company raised INGREZZA's full-year guidance to $2.875B-$2.925B. It also announced new clinical studies and an R&D Day on December 15, 2026.
How this was made
The 30-second read
Why it matters
The earnings beat and raised guidance provide a catalyst for short‑term price appreciation, while execution risk remains.
Market read
Strong quarterly performance and upward guidance make NBIX a notable trade idea in the biotech space.
What to watch
Potential dilution from stock‑based compensation and integration costs from Soleno acquisition.
Background
Neurocrine Biosciences (NBIX) released its unaudited Q3 2026 earnings, highlighting record product sales and new clinical programs.
Ticker impact
Neurocrine posted Q3 2026 results with $1.123 B revenue and raised full‑year INGREZZA sales guidance to $2.9 B.
likely upward as market prices in higher sales outlook
Revenue beat and guidance increase are fresh primary disclosures that can move the stock.
Market effects
Biotech sector may see broader optimism on neuro‑psychiatric drug pipelines.
U.S. biotech indices could see modest gains.
Limited to investors focused on U.S. listed biotech stocks.
Counterpoint
Guidance may be overly optimistic if upcoming clinical data disappoint.
Key entities
- CompanyNeurocrine Biosciences
U.S. biotech firm developing treatments for movement disorders.
- ExecutiveEiry W. Roberts, M.D.
Rejoined as Chief Medical Officer.
